Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more
Climb Bio Inc (CLYM) - Net Assets
Latest net assets as of December 2025: $160.47 Million USD
Based on the latest financial reports, Climb Bio Inc (CLYM) has net assets worth $160.47 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($167.74 Million) and total liabilities ($7.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $160.47 Million |
| % of Total Assets | 95.67% |
| Annual Growth Rate | 40.77% |
| 5-Year Change | -4.02% |
| 10-Year Change | N/A |
| Growth Volatility | 252.32 |
Climb Bio Inc - Net Assets Trend (2019–2025)
This chart illustrates how Climb Bio Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Climb Bio Inc (2019–2025)
The table below shows the annual net assets of Climb Bio Inc from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $160.47 Million | -24.26% |
| 2024-12-31 | $211.88 Million | +96.92% |
| 2023-12-31 | $107.60 Million | -16.41% |
| 2022-12-31 | $128.72 Million | -23.02% |
| 2021-12-31 | $167.20 Million | +675.24% |
| 2020-12-31 | $21.57 Million | +4.64% |
| 2019-12-31 | $20.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Climb Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28225900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.00% |
| Other Comprehensive Income | $435.00K | 0.27% |
| Other Components | $449.76 Million | 280.27% |
| Total Equity | $160.47 Million | 100.00% |
Climb Bio Inc Competitors by Market Cap
The table below lists competitors of Climb Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genus Power Infrastructures Limited
NSE:GENUSPOWER
|
$198.61 Million |
|
Medical Facilities Corporation
PINK:MFCSF
|
$198.66 Million |
|
ProKidney Corp.
NASDAQ:PROK
|
$198.67 Million |
|
SENCO GOLD LTD
NSE:SENCO
|
$198.69 Million |
|
Simulations Plus Inc
NASDAQ:SLP
|
$198.40 Million |
|
Artius II Acquisition Inc. Class A Ordinary Shares
NASDAQ:AACB
|
$198.37 Million |
|
Algoma Central Corporation
PINK:AGMJF
|
$198.30 Million |
|
San Juan Basin Royalty Trust
NYSE:SJT
|
$198.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Climb Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 211,881,000 to 160,475,000, a change of -51,406,000 (-24.3%).
- Net loss of 59,851,000 reduced equity.
- Other comprehensive income increased equity by 412,000.
- Other factors increased equity by 8,033,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-59.85 Million | -37.3% |
| Other Comprehensive Income | $412.00K | +0.26% |
| Other Changes | $8.03 Million | +5.01% |
| Total Change | $- | -24.26% |
Book Value vs Market Value Analysis
This analysis compares Climb Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.01x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.03x to 3.01x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $1.77 | $7.12 | x |
| 2020-12-31 | $1.85 | $7.12 | x |
| 2021-12-31 | $13.64 | $7.12 | x |
| 2022-12-31 | $4.89 | $7.12 | x |
| 2023-12-31 | $3.99 | $7.12 | x |
| 2024-12-31 | $4.40 | $7.12 | x |
| 2025-12-31 | $2.37 | $7.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Climb Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -37.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.05x
- Recent ROE (-37.30%) is above the historical average (-42.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -31.76% | 0.00% | 0.00x | 1.04x | $-8.61 Million |
| 2020 | -95.83% | 0.00% | 0.00x | 1.14x | $-22.82 Million |
| 2021 | -28.40% | 0.00% | 0.00x | 1.04x | $-64.20 Million |
| 2022 | -35.15% | 0.00% | 0.00x | 1.05x | $-58.12 Million |
| 2023 | -32.64% | 0.00% | 0.00x | 1.03x | $-45.88 Million |
| 2024 | -34.88% | 0.00% | 0.00x | 1.03x | $-95.09 Million |
| 2025 | -37.30% | 0.00% | 0.00x | 1.05x | $-75.90 Million |
Industry Comparison
This section compares Climb Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Climb Bio Inc (CLYM) | $160.47 Million | -31.76% | 0.05x | $198.54 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |